ID   UM-SCC-22A
AC   CVCL_7731
SY   UMSCC-22A; UMSCC22A; SCC22A; UMC-22a; UMC22a; UM-22A; University of Michigan-Squamous Cell Carcinoma-22A
DR   BTO; BTO:0002714
DR   cancercelllines; CVCL_7731
DR   Cosmic; 948033
DR   Cosmic; 1130357
DR   Cosmic; 2439752
DR   Cosmic; 2513913
DR   IARC_TP53; 25908
DR   Millipore; SCC076
DR   Wikidata; Q54990837
RX   DOI=10.1016/B978-0-12-333530-2.50007-1;
RX   PubMed=1958593;
RX   PubMed=9139877;
RX   PubMed=15287027;
RX   PubMed=17312569;
RX   PubMed=18006756;
RX   PubMed=19760794;
RX   PubMed=21868764;
RX   PubMed=23613873;
RX   PubMed=26122845;
RX   PubMed=28196595;
RX   PubMed=29156801;
RX   PubMed=31541927;
WW   https://tcpaportal.org/mclp/
CC   Part of: MD Anderson Cell Lines Project.
CC   Doubling time: 31 +- 4 hours (PubMed=9139877).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=31541927).
CC   Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Glu341Gln (c.1021G>C); Zygosity=Heterozygous (PubMed=31541927).
CC   Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Leu1935Val (c.5803C>G); Zygosity=Heterozygous (PubMed=31541927).
CC   Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Glu1679Ter (c.5035G>T); Zygosity=Homozygous (PubMed=31541927).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Heterozygous (PubMed=18006756; PubMed=23613873; PubMed=31541927).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.993+1G>T (IVS9+1G>T); ClinVar=VCV000634766; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=18006756; PubMed=23613873; PubMed=31541927).
CC   Omics: Deep exome analysis.
CC   Omics: Genome sequenced (low read coverage).
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Pharynx, hypopharynx; UBERON=UBERON_0001051.
ST   Source(s): Millipore; PubMed=19760794; PubMed=21868764
ST   Amelogenin: X
ST   CSF1PO: 10
ST   D13S317: 8,12
ST   D16S539: 9,11
ST   D18S51: 18
ST   D21S11: 28
ST   D3S1358: 16
ST   D5S818: 12
ST   D7S820: 8,9
ST   D8S1179: 11,13
ST   FGA: 22,24
ST   Penta D: 13
ST   Penta E: 12,18
ST   TH01: 6
ST   TPOX: 8,11
ST   vWA: 15,18 (Millipore; PubMed=19760794_passage_16)
ST   vWA: 18 (PubMed=19760794_passage_138; PubMed=21868764)
DI   NCIt; C4043; Hypopharyngeal squamous cell carcinoma
DI   ORDO; Orphanet_494547; Squamous cell carcinoma of the hypopharynx
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_7732 ! UM-SCC-22B
SX   Female
AG   59Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 27
//
RX   DOI=10.1016/B978-0-12-333530-2.50007-1;
RA   Carey T.E.;
RT   "Head and neck tumor cell lines.";
RL   (In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.79-120; Academic Press; New York (1994).
//
RX   PubMed=1958593; DOI=10.1002/gcc.2870030406;
RA   Bradford C.R., Kimmel K.A., Van Dyke D.L., Worsham M.J., Tilley B.J.,
RA   Burk D., del Rosario F., Lutz S., Tooley R., Hayashida D.J.S.,
RA   Carey T.E.;
RT   "11p deletions and breakpoints in squamous cell carcinoma: association
RT   with altered reactivity with the UM-E7 antibody.";
RL   Genes Chromosomes Cancer 3:272-282(1991).
//
RX   PubMed=9139877; DOI=10.1002/(SICI)1097-0215(19970502)71:3<410::AID-IJC18>3.0.CO;2-J;
RA   Welters M.J.P., Fichtinger-Schepman A.M.J., Baan R.A., Hermsen M.A.J.A.,
RA   van der Vijgh W.J.F., Cloos J., Braakhuis B.J.M.;
RT   "Relationship between the parameters cellular differentiation,
RT   doubling time and platinum accumulation and cisplatin sensitivity in a
RT   panel of head and neck cancer cell lines.";
RL   Int. J. Cancer 71:410-415(1997).
//
RX   PubMed=15287027; DOI=10.1002/gcc.20066;
RA   Takebayashi S., Hickson A., Ogawa T., Jung K.-Y., Mineta H., Ueda Y.,
RA   Grenman R., Fisher S.G., Carey T.E.;
RT   "Loss of chromosome arm 18q with tumor progression in head and neck
RT   squamous cancer.";
RL   Genes Chromosomes Cancer 41:145-154(2004).
//
RX   PubMed=17312569; DOI=10.1002/hed.20478;
RA   Lin C.J., Grandis J.R., Carey T.E., Gollin S.M., Whiteside T.L.,
RA   Koch W.M., Ferris R.L., Lai S.Y.;
RT   "Head and neck squamous cell carcinoma cell lines: established models
RT   and rationale for selection.";
RL   Head Neck 29:163-188(2007).
//
RX   PubMed=18006756; DOI=10.1158/1078-0432.CCR-07-1591;
RA   Friedman J., Nottingham L., Duggal P., Pernas F.G., Yan B., Yang X.-P.,
RA   Chen Z., Van Waes C.;
RT   "Deficient TP53 expression, function, and cisplatin sensitivity are
RT   restored by quinacrine in head and neck cancer.";
RL   Clin. Cancer Res. 13:6568-6578(2007).
//
RX   PubMed=19760794; DOI=10.1002/hed.21198;
RA   Brenner J.C., Graham M.P., Kumar B., Saunders L.M., Kupfer R.,
RA   Lyons R.H., Bradford C.R., Carey T.E.;
RT   "Genotyping of 73 UM-SCC head and neck squamous cell carcinoma cell
RT   lines.";
RL   Head Neck 32:417-426(2010).
//
RX   PubMed=21868764; DOI=10.1158/1078-0432.CCR-11-0690;
RA   Zhao M., Sano D., Pickering C.R., Jasser S.A., Henderson Y.C.,
RA   Clayman G.L., Sturgis E.M., Ow T.J., Lotan R., Carey T.E., Sacks P.G.,
RA   Grandis J.R., Sidransky D., Heldin N.-E., Myers J.N.;
RT   "Assembly and initial characterization of a panel of 85 genomically
RT   validated cell lines from diverse head and neck tumor sites.";
RL   Clin. Cancer Res. 17:7248-7264(2011).
//
RX   PubMed=23613873; DOI=10.1371/journal.pone.0061555;
RA   Martens-de Kemp S.R., Dalm S.U., Wijnolts F.M.J., Brink A.,
RA   Honeywell R.J., Peters G.J., Braakhuis B.J.M., Brakenhoff R.H.;
RT   "DNA-bound platinum is the major determinant of cisplatin sensitivity
RT   in head and neck squamous carcinoma cells.";
RL   PLoS ONE 8:E61555-E61555(2013).
//
RX   PubMed=26122845; DOI=10.1158/0008-5472.CAN-15-0528;
RA   Stoepker C., Ameziane N., van der Lelij P., Kooi I.E., Oostra A.B.,
RA   Rooimans M.A., van Mil S.E., Brink A., Dietrich R., Balk J.A.,
RA   Ylstra B., Joenje H., Feller S.M., Brakenhoff R.H.;
RT   "Defects in the Fanconi anemia pathway and chromatid cohesion in head
RT   and neck cancer.";
RL   Cancer Res. 75:3543-3553(2015).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=29156801; DOI=10.18632/oncotarget.21174;
RA   Kalu N.N., Mazumdar T., Peng S.-H., Shen L., Sambandam V., Rao X.-Y.,
RA   Xi Y.-X., Li L.-R., Qi Y., Gleber-Netto F.O., Patel A., Wang J.,
RA   Frederick M.J., Myers J.N., Pickering C.R., Johnson F.M.;
RT   "Genomic characterization of human papillomavirus-positive and
RT   -negative human squamous cell cancer cell lines.";
RL   Oncotarget 8:86369-86383(2017).
//
RX   PubMed=31541927; DOI=10.1016/j.oraloncology.2019.09.004;
RA   van Harten A.M., Poell J.B., Buijze M., Brink A., Wells S.I.,
RA   Leemans C.R., Wolthuis R.M.F., Brakenhoff R.H.;
RT   "Characterization of a head and neck cancer-derived cell line panel
RT   confirms the distinct TP53-proficient copy number-silent subclass.";
RL   Oral Oncol. 98:53-61(2019).
//